Gilead Sciences Inc (USD)
GILD
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range62.84 | 64.20
52-Wk Range60.89 | 70.50
Last Close63.15
Mkt Cap (m)79,893.95
Dividend yield3.99%
ISINUS3755581036
Volume18,685,066
Exchange VenueNAS

Company Profile

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Key Information
Price/Earning29.79
Price/Book3.88
Price/Sales3.62
P/CF9.09
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 18/09/2017
Annual Report
en 31/12/2018

Financials

Income Statement
USD201420152016201720182019
Revenue (m)24,89032,63930,39026,10722,127-
Operating Income (m)15,26522,19317,63314,1248,200-
Net Income (m)12,10118,10813,5014,6285,455-
Basic EPS7.9512.3710.083.544.20-
Avg. Diluted Shares Outstanding (m)1,6471,5211,3581,3191,308-
Balance Sheet
USD201420152016201720182019
Current Assets (m)17,71424,76320,44531,82335,836-
Non Current Assets (m)16,95027,07636,53238,46027,839-
Total Assets (m)34,66451,83956,97770,28363,675-
Current Liabilities (m)5,7769,8939,21911,63510,605-
Total Liabilities (m)------
Total Equity (m)15,42618,53418,88720,44221,387-
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)12,81820,32916,66911,8988,400-
Capital Expenditure (m)-557-747-748-590-924-
Figures are quoted in USD unless stated otherwise
0.00 (0.00%)
$
63.15
Last Price